enumeral biomedical holdings (ENUM) Key Developments
Enumeral Biomedical Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Month Ended September 30, 2014
Nov 14 14
Enumeral Biomedical Holdings, Inc. reported unaudited consolidated earnings results for the third quarter and nine month ended September 30, 2014. For the quarter, the company’s revenue was $70,408 against $140,840 a year ago. Loss from operations was $2,151,521 compared to $937,778 a year ago. Net loss before income taxes operations was $8,823,492 compared to $962,302 a year ago. Net loss was $8,823,492 or $0.22 per basic and diluted share compared to $962,302 or $0.26 per basic and diluted share a year ago.
For the nine months, the company’s revenue was $121,122 against $341,044 a year ago. Loss from operations was $4,424,024 compared to $2,607,262 a year ago. Net loss before income taxes operations was $11,220,397 compared to $2,690,550 a year ago. Net loss was $11,220,397 or $0.44 per basic and diluted share compared to $2,690,550 or $0.21 per basic and diluted share a year ago.
Enumeral Biomedical Holdings Appoints M. Isabel Chiu as Vice President of Translational and Clinical Sciences
Oct 21 14
Enumeral Biomedical Holdings, Inc. announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral's internal and external translational programs using human patient-derived tissue samples in ex vivo preclinical trials. Dr. Chiu oversees the operational, program management and strategic initiatives to support these goals. Prior to joining Enumeral, Dr. Chiu, served 10 years at AVEO Pharmaceuticals, most recently as Vice President, Translational Research, where she was instrumental in the creation of the company's proprietary "Human Response Platform" and was responsible for applying preclinical insights to guide the company's discovery, development and biomarker programs.
Enumeral Receives Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute to Advance Human Tissue Immuno-Oncology Profiling
Sep 17 14
Enumeral has been awarded a Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) for $999,967 over two years. The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of the contract. The NCI will be funding the entirety of the program, which will complement Enumeral's other internal research and development efforts. Small volume clinical specimens such as core biopsy or fine needle aspirates often contain limited numbers of cells and can be challenging to analyze with conventional technologies. This Phase II program utilizes Enumeral's platform to obtain multiplexed information from human tissue samples of limited cellularity, potentially addressing these challenges. Enumeral generated proof of concept in this area under a Phase I contract in 2012 and 2013.
Enumeral Appoints Kevin Sarney as Vice President of Finance and Chief Accounting Officer
Sep 15 14
Enumeral Biomedical Holdings, Inc. announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Prior to joining Enumeral, Mr. Sarney served as Vice President, Finance and Administration at Avaxia Biologics.
Enumeral Biomedical Holdings, Inc. Amends Certificate of Incorporation
Aug 8 14
Prior to the closing of the Merger, Enumeral Biomedical Holdings, Inc. amended and restated its Certificate of Incorporation. The amendment was approved and adopted by the company's Board of Directors and stockholders. The effective date of the amendment was July 31, 2014.